Humira RA labeling expansion
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Abbott's Humira (adalimumab) label was updated to reflect new data that the monoclonal antibody inhibits irreversible joint damage in patients with rheumatoid arthritis for up to five years. A five-year study conducted in patients with long-standing RA demonstrated that roughly 60 percents of patients showed no radiographic progression after five years. Patients with inadequate response to methotrexate received adalimumab plus methotrexate to evaluate radiographic disease progression and safety of the therapy...
You may also be interested in...
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.